<DOC>
	<DOCNO>NCT01211249</DOCNO>
	<brief_summary>Part A : 30 patient suffer active rheumatoid arthritis despite continued treatment methotrexate receive daily two capsule contain either GLPG0259 ( 25 mg/capsule ) match placebo , 12 week . In course study patient examine severity disease , well adverse effect may occur . If need , dose may split one capsule twice daily , reduce one capsule 25 mg. Part B : If result Part A suggest test medication therapeutic advantage placebo well-tolerated , patient recruit Part B , various dosage assess . These dosage establish base result Part A .</brief_summary>
	<brief_title>GLPG0259 Methotrexate-refractory Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Must active RA ( ≥5 tender painful joint motion ≥5 joint swell AND Creactive protein ( CRP ) concentration ≥1.5 mg/dL ) . Must methotrexate ≥6 month stable dose 7.525 mg/week ≥12 week , continue throughout study ; If oral steroid , dose ≤10 mg/day prednisone eq stable ≥4 week prior screen ; If NSAIDs , must stable dose ≥2 week prior screen ; Women must negative pregnancy test unless surgically sterile postmenopausal ≥1 year ; Women childbearing potential must use medically acceptable mean birth control agree continue use study ≥12 week last dose study drug . Informed consent Must receive treatment DMARDs , background methotrexate ; Must receive receive RA treatment biological agent , except administer clinical study ≥six month prior screen ( 12 month rituximab B cell deplete agent ) ; Must receive treatment cytotoxic agent , methotrexate , screen ( e.g . chlorambucil , cyclophosphamide , nitrogen mustard , alkylating agent ) ; Must receive intraarticular parenteral corticosteroid injection within four week prior screen ; Must regularly use aspirin anticoagulant medication ; Must know hypersensitivity study drug ingredient significant allergic reaction drug determine Investigator , anaphylaxis , require hospitalization ; Must positive serology human immunodeficiency virus ( HIV ) 1 2 hepatitis B C , history HIV hepatitis cause exception hepatitis A ; Must history inflammatory rheumatological disorder RA ; Must undergone ( plan ) surgical treatment RA ; Must symptom clinically significant illness RA ( include limit cardiopulmonary , renal , metabolic , hematologic , psychiatric disorder ) within three month prior screen ; Must history active infection require intravenous antibiotic within past four week ; Must history malignancy within past five year ( except basal cell carcinoma skin carcinoma situ cervix treat evidence recurrence ) ; Must history tuberculosis ( TB ) infection determine positive diagnostic TB test result ( define positive QuantiFERON TB Gold test ) , AND recent chest radiograph ( posterioranterior lateral view ) , read qualified radiologist , evidence current active TB old inactive TB . Must administer live vaccine within four week prior screen ; Must participate investigational drug/device clinical study within four week prior screen , biological agent clinical study within six month prior screen , B celldepleting agent clinical study within 12 month prior screen ; Must history within previous two year current evidence drug alcohol abuse ; Must condition circumstance opinion Investigator may make subject unlikely unable complete study comply study procedures requirement , may pose risk patient 's safety .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Methotrexate-refractory</keyword>
</DOC>